Clin2
NCT07049328Possibly a fitRecruiting

Study of HCW9302 for Alopecia Areata

Alopecia Areata(AA)

Part of Skin clinical trials.

This trial tests a new drug, HCW9302, that targets the immune system to help hair regrow in people with alopecia areata (including extensive forms like totalis or universalis). It may be an option for adults who have not responded well to other treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • Adults aged 18–70 (women) or 18–60 (men) with alopecia areata (including ophiasis, totalis, or universalis forms).
  • Must not have other types of hair loss (like diffuse shedding or scarring alopecia).
  • Cannot have used certain immune-targeting drugs (like IL-2 analogs) or hair growth treatments (like minoxidil) recently.
  • Must not have a history of diabetes, heart issues, or active infections.
  • Able to use effective birth control (if of childbearing potential) and attend study visits.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06826196Recruiting· Phase 1/Phase 2
Testing a new shot for patchy hair loss (alopecia areata)

This study tests a new medicine called ALD-102, given as a small shot in the scalp, to see if it helps hair grow back in people with alopecia areata. It is an early-stage trial looking at safety, how the body handles the drug, and whether it works.

Thousand Oaks, California
NCT07482423Not yet recruiting· Phase 1/Phase 2
New Biologic Treatment for Male and Female Pattern Baldness

This study tests a new experimental biologic treatment, XVIE, for male and female pattern baldness. It aims to see if the treatment is safe and can help regrow hair in people with mild to moderate thinning.

Orlando, Florida
NCT07533006Recruiting· Phase 2
Testing LY4005130 for severe hair loss (alopecia areata)

This study tests whether a new drug called LY4005130 can help regrow hair in adults with severe alopecia areata (an autoimmune condition causing patchy or widespread hair loss). The trial is looking for people who have lost a significant amount of hair and haven't seen it grow back on its own for at least 6 months.

Fremont, California
NCT07205159Recruiting· Phase 1
A study of FB102 for severe alopecia areata

This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.

Saint Leonards, New South Wales (nsw)
NCT06012240Recruiting· Phase 3
Testing Upadacitinib for Severe Alopecia Areata

This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.

Birmingham, Alabama
NCT07311564Recruiting· Phase 2
Study of LAD603 for adults with severe alopecia areata

This trial tests a new medication called LAD603 for people with severe to very severe alopecia areata, a condition causing significant hair loss. It aims to see if the drug can help regrow hair.

Omaha, Nebraska

Hear when a new Alopecia Areata(AA) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.